BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 14571722)

  • 1. Therapeutic effect of oral recombinant human granulocyte macrophage-colony stimulating factor in radiotherapy-induced esophagitis.
    Koc M; Onuk MD; Koruk M; Memik F
    Hepatogastroenterology; 2003; 50(53):1297-300. PubMed ID: 14571722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral administration of recombinant human granulocyte macrophage colony-stimulating factor in the management of radiotherapy-induced esophagitis.
    Koukourakis MI; Flordellis CS; Giatromanolaki A; Koukouraki S; Kapsoritakis A; Potamianos S; Retalis G; Sivridis E; Salsaa B; Harris AL; Maragoudakis MI
    Clin Cancer Res; 1999 Dec; 5(12):3970-6. PubMed ID: 10632327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of irradiation-induced mucositis with growth factors (rhGM-CSF) in patients with head and neck cancer.
    Wagner W; Alfrink M; Haus U; Matt J
    Anticancer Res; 1999; 19(1B):799-803. PubMed ID: 10216495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.
    Ryu JK; Swann S; LeVeque F; Scarantino CW; Johnson D; Chen A; Fortin A; Pollock J; Kim H; Ang KK
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):643-50. PubMed ID: 17293228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy.
    Takeda K; Nemoto K; Saito H; Ogawa Y; Takai Y; Yamada S
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):626-9. PubMed ID: 15936536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.
    Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Lusso MR; Camboni P; Ferreli L; Mocci M; Perboni S; Mura L; Madeddu C; Macciò A
    Oncol Rep; 2003; 10(1):197-206. PubMed ID: 12469169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: evaluation of clinical and dosimetric parameters.
    Topkan E; Yavuz MN; Onal C; Yavuz AA
    Lung Cancer; 2009 Mar; 63(3):393-9. PubMed ID: 18691789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy.
    Rodríguez N; Algara M; Foro P; Lacruz M; Reig A; Membrive I; Lozano J; López JL; Quera J; Fernández-Velilla E; Sanz X
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):810-7. PubMed ID: 18755556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery.
    Patel AB; Edelman MJ; Kwok Y; Krasna MJ; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1106-12. PubMed ID: 15519781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study.
    Valcárcel D; Sanz MA; Sureda A; Sala M; Muñoz L; Subirá M; Laborda R; Clopés A; Sierra J
    Bone Marrow Transplant; 2002 May; 29(9):783-7. PubMed ID: 12040477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endoscopic findings of esophagitis in concurrent chemo-radiotherapy for lung cancer].
    Watanabe H; Hirota S; Soejima T; Honda K; Kono K; Hishikawa Y; Obayasi K; Takada Y
    Nihon Igaku Hoshasen Gakkai Zasshi; 1998 May; 58(6):271-6. PubMed ID: 9656695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].
    Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ
    Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
    Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
    Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.
    Kim TH; Cho KH; Pyo HR; Lee JS; Han JY; Zo JI; Lee JM; Hong EK; Choi IJ; Park SY; Shin KH; Kim DY; Kim JY
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):995-1002. PubMed ID: 15990000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial.
    Wu HG; Song SY; Kim YS; Oh YT; Lee CG; Keum KC; Ahn YC; Lee SW
    Cancer; 2009 Aug; 115(16):3699-708. PubMed ID: 19514089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy.
    Belderbos J; Heemsbergen W; Hoogeman M; Pengel K; Rossi M; Lebesque J
    Radiother Oncol; 2005 May; 75(2):157-64. PubMed ID: 15890421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
    Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
    J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy.
    Wei X; Liu HH; Tucker SL; Liao Z; Hu C; Mohan R; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):100-7. PubMed ID: 16839700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction therapy of loco-regional non-small-cell lung cancer with reliable response and low toxicity (low dose radiotherapy sensitizes tumor to subsequent chemotherapy?).
    Takita H; Shin KH; Soh AY; Yi WS; Wilding G
    Lung Cancer; 2009 Mar; 63(3):387-92. PubMed ID: 18676056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer.
    Chapet O; Kong FM; Lee JS; Hayman JA; Ten Haken RK
    Radiother Oncol; 2005 Nov; 77(2):176-81. PubMed ID: 16256230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.